
884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies
Teichner, Paula, Cutrell, Amy, D’Amico, Ronald, Dorey, David, Griffith, Sandy, Harrington, Conn M, Huang, Jenny, Hudson, Krischan J, Margolis, David, Mrus, Joseph, Polli, Joseph, Spreen, William, WillVolume:
6
Journal:
Open Forum Infectious Diseases
DOI:
10.1093/ofid/ofz359.043
Date:
October, 2019
Fichier:
PDF, 303 KB
2019